β οΈ Mechanism
Fluvoxamine inhibits CYP1A2 and CYP2C19, which metabolize melatonin. Combined use dramatically raises melatonin levels.
π Effect
Excessive melatonin levels; excessive daytime sedation
π Management
Avoid combination or reduce melatonin dose significantly.
Plain Language Summary
This combination can be risky because it may cause melatonin levels to rise much higher than normal. Fluvoxamine slows down the way your body breaks down melatonin, which can lead to excessive sleepiness during the day.
Source
HΓ€rtter S et al. Clin Pharmacol Ther 2001
Supporting Research
Interventions for preventing delirium in hospitalised non-ICU patients
Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials
Pharmacological interventions for prevention of weight gain in people with schizophrenia
Prevention of depression in adults with long-term physical conditions
Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis
Does melatonin administration reduce the incidence of postoperative delirium in adults? Systematic review and meta-analysis
Second-generation antidepressants for preventing seasonal affective disorder in adults
Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries
Medical Disclaimer: This interaction record is for informational and educational purposes only and does not constitute medical advice. Drug-supplement interactions can be dangerous. Always consult your healthcare provider or pharmacist before combining any supplement with prescription medications. Do not stop or change any medication without professional guidance.